Comparative Study of Budesonide Inhalation Suspension and Montelukast in Young Children With Mild Persistent Asthma

RESULTS. Children who received montelukast experienced 53% fewer days with “worse asthma symptoms” compared with children who received placebo (3.9% vs 8.3%; P .02). In addition, there was a 78% reduction in the number of unscheduled visits to a physician for asthma (4 vs 18; P .011). These improvements were seen in patients with and without cold symptoms. Among boys, the greatest benefit from montelukast was seen in those aged 2 to 5 years. Girls benefited most from montelukast when they were between the ages of 10 and 14 years.